Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
Key Highlights
- ➤Valneva (VALN) schedules U.S. and European investor conference presentations.
- ➤Lyme vaccine regulatory decisions expected within the next 12 months.
- ➤Pfizer partnership could drive future value if Lyme vaccine gains approval.
- ➤Valneva will discuss R&D pipeline progress and future value creation.
Lyon (France), October 14, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in meetings with institutional investors at upcoming investor conferences in the United States and Europe.
In addition to meeting with investors, Valneva will host moderated “fireside chat” presentations to discuss the Company’s key value drivers and upcoming catalysts, primarily the regulatory outlook for the Company’s Lyme disease vaccine candidate, which is partnered with Pfizer, and for which regulatory decisions are expected within the next 12 months. Valneva will also discuss its R&D pipeline progress and expectations for future value creation if the Lyme vaccine candidate is successfully approved and commercialized by Pfizer.
Get started
Create a free account to read the full story.